Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
California’s Department of Motor Vehicles has postponed a planned 30-day suspension of Tesla’s dealer and manufacturer licenses after the automaker ceased using the term "autopilot" in vehicle marketing within the state. The reprieve arrives as Tesla and other electric vehicle makers face a downturn in demand following the end of important sales-bo…
Oil futures nudged down as progress in US-Iran negotiations reduced near-term supply disruption concerns, while reports of recovering output at Kazakhstan's Tengiz field and forthcoming U.S. inventory reports kept traders cautious. Brent and WTI traded near two-week lows, and market attention shifted to weekly API and EIA data that could confirm re…
U.S. stock futures edged lower Tuesday evening after a modest, uneven rebound in technology shares. Market participants are positioning for a series of economic releases and the Federal Reserve's January meeting minutes, which are expected to offer additional clarity on the central bank's interest-rate outlook. Investors monitored heavyweights incl…
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 10,348 shares of common stock on February 12, 2026, in a filing that shows the transaction was executed to satisfy tax withholding tied to vested restricted stock units. The sale, executed at a weighted average price of $9.04 for a total of $93,545, comes as the company reported positive P…
Ocular Therapeutix COO Donald Notman sold 11,446 shares on February 12, 2026, for $103,471 at a weighted average price of $9.04. The sale left him with 366,356 shares. The transaction coincides with the company reporting a Phase 3 superiority result for its investigational wet age-related macular degeneration treatment AXPAXLI, a reaffirmation of a…
Gold prices stabilised in Asian trade following a more than 2% decline the prior session, a fall prompted by improving risk appetite after reported progress in U.S.-Iran negotiations and a stronger U.S. dollar. Market participants awaited the Federal Reserve's January meeting minutes and the U.S. personal consumption expenditures inflation report f…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 7,863 shares on February 12, 2026 to satisfy tax withholding tied to vested restricted stock units, leaving her with 318,417 shares. The transaction coincides with the company’s disclosure of positive Phase 3 SOL-1 results for AXPAXLI in wet age-related macular degeneration, an RBC Cap…
Ocular Therapeutix Executive Chairman, President and CEO Pravin Dugel sold 124,882 shares on February 12, 2026, in a transaction totaling $1.13 million to satisfy tax obligations tied to restricted stock unit vesting. The company also disclosed a successful Phase 3 superiority outcome for its wet age-related macular degeneration candidate AXPAXLI, …
Huntington Ingalls (HII) has lagged some peers in rerating, but recent program wins, robust free cash flow, and a cleaner balance sheet point to a constructive trade. I am upgrading HII to a long trade at $418.25 with a $475 target and a $380 stop, horizon 180 trading days. The risk/reward is attractive given a $16.4B market cap, $794M annual free …
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen (BIIB), purchased three shares of the company's common stock on February 12, 2026, at $195.035 per share for a total of $585. The purchase was recorded on a Form 4 filing and follows strong recent market performance for Biogen, which trades near its 52-week high. Murphy also …
On December 18, 2025, Samsara Opportunity Fund, L.P. bought 479,847 shares of Kalaris Therapeutics at $10.42 per share in a privately negotiated transaction valued at $5,000,005. The trade raises Samsara Opportunity Fund’s direct stake to 1,979,847 shares and follows a disposition from Samsara BioCapital, L.P., which now holds 10,968,234 shares. Ka…
The Reserve Bank of New Zealand held its official cash rate at 2.25%, noting that headline inflation rose to 3.1% in the December 2025 quarter but is expected to fall back within the 1% to 3% target band by the March quarter and drift toward the 2% midpoint over the next year. The central bank said earlier rate cuts have supported a gradual recover…
Micron is trading near $400 after a year of dramatic DRAM/NAND repricing and accelerating revenue. Institutional allocators are rotating in, earnings momentum is visible, and balance-sheet metrics support risk-taking. This trade targets continued DDR5-driven pricing power and share gains into 2026 while protecting capital with a strict stop.
California Attorney General Rob Bonta is creating an AI oversight unit while pressing an investigation into Elon Musk-backed xAI after allegations its Grok chatbot produced sexualized images of real people, including potentially minors. The attorney general's office has sent a cease-and-desist to xAI, is seeking confirmation that the conduct has st…
Equinix Inc.'s Chief Financial Officer, Keith D. Taylor, sold 2,000 shares on February 12, 2026, for $956.44 each, generating roughly $1.9 million. The company has issued 2026 revenue and adjusted funds from operations per share guidance that exceeded Wall Street expectations, reported record bookings and monthly recurring revenue growth, and promp…
Saira Ramasastry, a director at Mirum Pharmaceuticals (MIRM), sold 2,000 shares on February 13, 2026, under a prearranged Rule 10b5-1 plan and exercised options for 2,000 shares the same day. The stock is trading close to its 52-week high after Mirum reported preliminary 2025 product sales that exceeded guidance, projected significant growth for 20…
Envoy Medical Interim Chief Financial Officer Robert Potashnick purchased 212,500 shares of Class A Common Stock for $85,000 and acquired warrants to buy an additional 340,000 shares. The company also reported reaching the midway point in enrollment for its pivotal study of the Acclaim cochlear implant and disclosed issuance of an Australian patent…
Dawn Christine Maroney, president of Alignment Healthcare, sold 30,000 shares on February 17, 2026, for a total of $618,990 under a Rule 10b5-1 plan. The transaction occurred at prices between $20.05 and $20.99, near the quoted share price of $20.59. The company is set to report earnings on February 26, and analysts have recently lifted price targe…
Los Angeles Lakers center Deandre Ayton, a native of the Bahamas, was briefly detained by authorities at Lynden Pindling International Airport on suspicion of possessing a small quantity of marijuana. His lawyer said investigators found the substance was not in Ayton's bag and that it belonged to someone else; Ayton was released quickly. The Royal …
CSL Ltd has entered an exclusive licensing agreement with Eli Lilly for clazakizumab, a treatment targeting heart and kidney disease. CSL will receive a $100 million upfront payment and may collect milestone payments and royalties. The announcement coincided with a modest intraday rise in CSL shares after the stock had plunged nearly 17% the previo…
The U.S. dollar remained largely steady as investors balanced renewed geopolitical concerns with reports of diplomatic progress in Geneva and awaited minutes from the Federal Reserve’s January meeting. Asian markets were thin due to Lunar New Year holidays, while currency moves responded to Japanese manufacturing data, an expected hold by New Zeala…
Alnylam Pharmaceuticals Executive Vice President and Chief R&D Officer Pushkal Garg sold 2,242 shares on February 13, 2026, to satisfy minimum statutory tax withholding tied to the vesting of performance-based stock units. The transaction totaled $695,201 at a weighted average price of $310.0808. The filing outlines the PSU vesting, Garg’s post-sal…
Monolithic Power Systems Inc. Chief Executive Officer Michael Hsing sold 31,260 shares on February 12, 2026, for about $38.6 million under a Rule 10b5-1 plan. The transactions occurred at prices between $1,155.71 and $1,217.12, while the stock trades near its 52-week high of $1,250. The company reported robust fourth-quarter 2025 results and saw se…
Avidbank Holdings Inc. director Mike Rosinus sold 5,076 shares on February 17, 2026, at $30.172 per share for a total of $153,153. After the transaction Rosinus holds 16,680 shares directly and 183,122 shares indirectly. Separately, the company reported fourth-quarter fiscal 2025 results with EPS of $0.65 versus an analyst forecast of $0.76, and re…
Pay settlements reported by employers in the UK rose to a median basic award of 3.2% in the three months to the end of January, edging up from 3% recorded across 2025. The Brightmine sample suggests an initial tilt toward higher settlements as firms compete for staff, though employers remain cautious amid broader economic challenges and a spring in…
